论文部分内容阅读
食管癌是我国常见的恶性肿瘤之一,死亡率高,预后较差,总5年生存率20%左右,70%~80%的患者在就诊时已属晚期,中位生存期为4个月~8个月。临床上对这些患者主要采用姑息性药物治疗。食管癌单药化疗有效率低(RR 15%~30%),缓解期短(<4个月)。紫杉醇(PTX)、多西紫杉醇(TXT)、伊立替康(CPT-11)、长春瑞宾
Esophageal cancer is one of the common malignant tumors in our country. The mortality is high and the prognosis is poor. The total 5-year survival rate is about 20%. 70% -80% of the patients are already treated at the advanced stage and the median survival time is 4 months ~ 8 months. Clinically, these patients mainly use palliative drug therapy. Chemotherapy for esophageal cancer is less effective (RR 15% -30%) and has a shorter response time (<4 months). Paclitaxel (PTX), docetaxel (TXT), irinotecan (CPT-11), vinorelbine